Brazil · Delayed Price · Currency is BRL Raia Drogasil Earnings Call Transcripts
Fiscal Year 2025
-
Record Q4 2025 results with 23% retail growth, 170 bps market share gain, and strong digital expansion. Strategic 4Bio sale sharpened focus on core retail, while disciplined capital allocation and operational efficiency drove margin improvements.
-
Q3 2025 saw robust revenue and EBITDA growth, driven by strong retail and digital performance, improved cost control, and record market share. Inventory and cash cycle improvements, new distribution centers, and digital expansion position the company for continued growth.
-
Strong sales and digital growth drove a 12% revenue increase and record net income, with market share gains across all regions. Inventory and expense efficiencies improved margins, while digital and retail segments both delivered robust performance.
-
1Q25 results missed expectations due to calendar and one-off effects, with sales up 10.8% and EBITDA margin down to 6%. Market share increased, digital sales grew 40%, and cost controls plus targeted promotions are underway to offset margin pressures.
Fiscal Year 2024
-
2024 saw strong revenue and digital growth, with 300 new stores and market share gains, but Q4 was impacted by weak cosmetics sales and margin pressures from tax and mix effects. 2025 will focus on organic expansion, digital, and efficiency to offset regulatory and macroeconomic headwinds.
-
Q3 saw record revenue, margin expansion, and robust digital growth, with 72 new stores opened and strong free cash flow. Market share and customer satisfaction remain high, and management expects continued margin gains and expansion into Q4.
-
Q2 2024 saw 15.4% revenue growth to BRL 10.4 billion, with digital sales up 44% and mature stores outpacing inflation. Gross margin was pressured by regulatory changes, but strong expansion, customer loyalty, and digital investments drove market share gains and robust profitability.